Tag Archives: Acute

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »

Acute flaccid myelitis

Centers for Disease Control and Prevention website. Acute flaccid myelitis. www.cdc.gov/acute-flaccid-myelitis/index.html. Updated October 22, 2018. Accessed October 30, 2018. Genetic and Rare Diseases Information Center website. Acute flaccid myelitis. US Department of Health and Human Services. National Institute of Health. rarediseases.info.nih.gov/diseases/13142/acute-flaccid-myelitis. Updated October 9, 2018. Accessed October 30, 2018 Messacar K, Modlin JF, Abzug MJ.… Read More »

FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza

FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza Print this page October 24, 2018 — Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48… Read More »